Adrenomedullin and truncated peptide adrenomedullin(22-52) affect chondrocyte response to apoptotis in vitro:

Frédéric Velard1, Aurore Chatron-Colliet1, Dominique Côme1

  • 1INSERM, UMR-S 1132 Bioscar, Centre Viggo Petersen, Hôpital Lariboisière, 2, Rue Ambroise Paré, 75010, Paris, France.

Scientific Reports
|October 8, 2020
PubMed

Insights

Adrenomedullin (AM) protects against osteoarthritis by reducing chondrocyte apoptosis. AM significantly decreased cell death and Fas receptor expression in bovine articular chondrocytes, suggesting potential therapeutic applications.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Osteoarthritis Research

Background:

  • Chondrocyte apoptosis plays a key role in osteoarthritis (OA) development.
  • Anti-apoptotic compounds are being explored for OA prevention and treatment.

Purpose of the Study:

  • To investigate the effects of adrenomedullin (AM) and its truncated form AM(22-52) on chondrocyte apoptosis.
  • To assess the potential of AM as a therapeutic agent for OA.

Main Methods:

  • Bovine articular chondrocytes (BACs) were cultured under hypoxia and treated with Fas ligand (Fas-L) to induce apoptosis.
  • AM and AM(22-52) treatments were applied, and apoptosis markers (caspase-3 activity, cell death, Fas expression) were measured.
  • Expression of AM, CLR, RAMP, and HIF-1α was assessed using immunostaining and RT-qPCR.

Main Results:

  • AM significantly reduced Fas-L-induced chondrocyte apoptosis, decreasing caspase-3 activity by 35% (p=0.03).
  • AM treatment led to significantly reduced cell death and downregulated Fas expression compared to AM(22-52).
  • Hypoxia-inducible factor 1α (HIF-1α), calcitonin receptor-like receptor (CLR), and receptor activity-modifying protein 2 (RAMP2) were expressed in BACs.

Conclusions:

  • Adrenomedullin (AM) effectively decreases chondrocyte apoptosis by downregulating the Fas receptor.
  • AM demonstrates potential as a novel therapeutic strategy for osteoarthritis.
  • Further research into AM-based therapies for OA is warranted.

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K